PPBT Valuation

Purple Biotech Ltd

Add to Watchlist

Advanced Chart

0.575

-0.005(-0.861%)1D

Overview
Forecast
Valuation
Earnings

PPBT Relative Valuation

PPBT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PPBT is overvalued; if below, it's undervalued.

Historical Valuation

Purple Biotech Ltd (PPBT) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -6.52. The fair price of Purple Biotech Ltd (PPBT) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：0.58

Fair

-0.65

Trailing

Forward

0.00

EV/EBITDA

Purple Biotech Ltd. (PPBT) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-0.01

EV/EBIT

Purple Biotech Ltd. (PPBT) has a current EV/EBIT of -0.01. The 5-year average EV/EBIT is -0.80. The thresholds are as follows: Strongly Undervalued below -3.02, Undervalued between -3.02 and -1.91, Fairly Valued between 0.32 and -1.91, Overvalued between 0.32 and 1.43, and Strongly Overvalued above 1.43. The current Forward EV/EBIT of -0.01 falls within the Historic Trend Line -Fairly Valued range.

0.00

Purple Biotech Ltd. (PPBT) has a current PS of 0.00. The 5-year average PS is 1.94. The thresholds are as follows: Strongly Undervalued below -4.85, Undervalued between -4.85 and -1.45, Fairly Valued between 5.33 and -1.45, Overvalued between 5.33 and 8.72, and Strongly Overvalued above 8.72. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Purple Biotech Ltd. (PPBT) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.65. The thresholds are as follows: Strongly Undervalued below -5.77, Undervalued between -5.77 and -2.56, Fairly Valued between 3.85 and -2.56, Overvalued between 3.85 and 7.06, and Strongly Overvalued above 7.06. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-0.61

P/FCF

Purple Biotech Ltd. (PPBT) has a current P/FCF of -0.61. The 5-year average P/FCF is -2.35. The thresholds are as follows: Strongly Undervalued below -8.07, Undervalued between -8.07 and -5.21, Fairly Valued between 0.51 and -5.21, Overvalued between 0.51 and 3.36, and Strongly Overvalued above 3.36. The current Forward P/FCF of -0.61 falls within the Historic Trend Line -Fairly Valued range.

Purple Biotech Ltd (PPBT) has a current Price-to-Book (P/B) ratio of 9.93. Compared to its 3-year average P/B ratio of 85.22 , the current P/B ratio is approximately -88.35% higher. Relative to its 5-year average P/B ratio of 129.84, the current P/B ratio is about -92.35% higher. Purple Biotech Ltd (PPBT) has a Forward Free Cash Flow (FCF) yield of approximately -145.71%. Compared to its 3-year average FCF yield of -118.47%, the current FCF yield is approximately 22.99% lower. Relative to its 5-year average FCF yield of -77.96% , the current FCF yield is about 86.90% lower.

9.84

P/B

Median3y

85.22

Median5y

129.84

-145.72

FCF Yield

Median3y

-118.47

Median5y

-77.96

Competitors Valuation Multiple

The average P/S ratio for PPBT's competitors is 0.00, providing a benchmark for relative valuation. Purple Biotech Ltd Corp (PPBT) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Lexaria Bioscience Corp

Hoth Therapeutics Inc

Loss

20.87M

CLRB.O

Cellectar Biosciences Inc

Performance Decomposition

Market capitalization of PPBT increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of PPBT in the past 1 year is driven by Unknown.